Skip to content

The application of vericiguat in ischemia-reperfusion injury during emergency PCI in patients with acute myocardial infarction

The application of vericiguat in ischemia-reperfusion injury during emergency PCI in patients with acute myocardial infarction

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089634
Enrollment
Unknown
Registered
2024-09-12
Start date
2024-09-16
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction (AMI)

Interventions

Vericiguat Group:Vericiguat + Standard AMI Medication + Emergency PCI
Standard Treatment Group:Standard AMI Medication + Emergency PCI

Sponsors

Shanghai Seventh People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years; 2. All patients with acute myocardial infarction (AMI) are from our hospital and have undergone PCI treatment within 12 hours of onset; 3. Patients have signed informed consent and are able to participate in outpatient follow-up.

Exclusion criteria

Exclusion criteria: 1. Clinically diagnosed AMI patients with negative angiography results; 2. Patients who received thrombolytic therapy prior to emergency PCI; 3. Patients taking corticosteroids, immunosuppressants, or other drugs that affect blood inflammatory cytokine levels; 4. Severe hepatic or renal insufficiency; 5. Patients with psychiatric disorders; 6. Participation in other clinical trials within the past 3 months; 7. Pregnant or breastfeeding women, or those planning to become pregnant; 8. Patients deemed by the investigator to have poor compliance and unable to strictly follow the protocol; 9. Any other condition deemed unsuitable for the trial by the investigator, such as poor compliance or difficulty with follow-up.

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiovascular Events (MACE);

Secondary

MeasureTime frame
Left Ventricular Ejection Fraction (LVEF);Troponin;N-terminal pro b-type natriuretic peptide (NT-proBNP);

Countries

China

Contacts

Public ContactZixuan Lu

Shanghai Seventh People's Hospital

zixuan76@163.com+86 138 1750 2039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026